NEW YORK, Nov. 9 (GenomeWeb News) - Gentel will combine its custom multiplex immunoassay development service with Abnova's high-throughput protein and antibody content-manufacturing capabilities, Gentel Biosurfaces said today.
GenTel's PATH Protein MicroArray System is based on ultra-thin nitrocellulose surface chemistry developed specifically for antibody arrays.
GenTel, which is privately held, will develop and offer multiplex immunoassays using protein content from Abnova, the company said.
Taiwan-based Abnova specializes in high throughput, in vitro wheat germ protein expression and monoclonal antibody production.
Financial details were not disclosed.